Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo

Blood

Volumn 104, Issue 5, 2004, Pages 1411-1418

  Pfister, Heiko ^b   Ollert, Markus ^b   Fröhlich, Leopold F ^b   Quintanilla Martinez, Leticia ^b   Colby, Thomas V ^b   Specks, Ulrich ^b   Jenne, Dieter E ^a  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LEUKOCYTE ELASTASE; LIPOPOLYSACCHARIDE; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; CELL SURFACE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; IN VIVO STUDY; INFLAMMATION; KIDNEY; KNOCKOUT MOUSE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PANNICULITIS; PATHOGENICITY; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SEQUENCE HOMOLOGY; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 4444272368     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0267     Document Type: Article

References (56)

1. Van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1:425-429.
2. Savige J, Davies D, Falk RJ, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int. 2000;57:846-862.
3. Jenne DE, Tschopp J, Lüdemann J, Utecht B, Gross WL. Wegener's autoantigen decoded. Nature. 1990;346:520.
4. Specks U. What you should know about PR3-ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA. Arthritis Res. 2000;2:263-267.
5. Nölle B, Specks U, Lüdemann J, et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med. 1989;111:28-40.
6. Tervaert JWC, van der Woude FJ, Fauci AS, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med. 1989;149:2461-2465.
7. Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum. 1993;36:365-371.
8. Tervaert JWC, Huitema MG, Hene RJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titer. Lancet. 1990;336:709-711.
9. Stegeman CA, Tervaert JWC, Kallenberg CG. Anti-neutrophil cytoplasmic antibodies: tools for diagnosis and follow-up in systemic vasculitis. Ann Med Interne (Paris). 1994;145:523-532.
10. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000;43:2025-2033.
11. Choi HK, Lamprecht P, Niles JL, Gross WL, Merkel PA. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum. 2000;43:226-231.
12. Wu YY, Hsu TC, Chen TY, et al. Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection. Clin Exp Immunol. 2002;128:347-352.
13. Pudifin DJ, Duursma J, Gathiram V, Jackson TF. Invasive amoebiasis is associated with the development of anti-neutrophil cytoplasmic antibody. Clin Exp Immunol. 1994;97:48-51.
14. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med. 1997;126:866-873.
15. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum. 1998;41:1521-1537.
16. Hewins P, Tervaert JW, Savage CO, Kallenberg CG. Is Wegener's granulomatosis an autoimmune disease? Curr Opin Rheumatol. 2000;12:3-10.
17. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87:4115-4119.
18. Weidner S, Neupert W, Goppelt-Strübe M, Rupprecht HD. Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro. Arthritis Rheum. 2001;44:1698-1706.
19. Gilligan HM, Bredy B, Brady HR, et al. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med. 1996;184:2231-2241.
20. Moosig F, Csernok E, Kumanovics G, Gross WL. Opsonization of apoptotic neutrophils by antineutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-α). Clin Exp Immunol. 2000;122:499-503.
21. Harper L, Cockwell P, Adu D, Savage CO. Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int. 2001;59:1729-1738.
22. Brooks CJ, King WJ, Radford DJ, et al. IL-1 beta production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies: relevance to systemic vasculitis. Clin Exp Immunol. 1996;106:273-279.
23. Cockwell P, Brooks CJ, Adu D, Savage CO. Interleukin-8: a pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int. 1999;55:852-863.
24. Ralston DR, Marsh CB, Lowe MP, Wewers MD. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, α1-antitrypsin, and Fcγ receptors. J Clin Invest. 1997;100:1416-1424.
25. Grimminger F, Hattar K, Papavassilis C, et al. Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. J Exp Med. 1996;184:1567-1572.
26. Sibelius U, Hattar K, Schenkel A, et al. Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response. J Exp Med. 1998;187:497-503.
27. Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120:12-17.
28. Stegeman CA, Tervaert JWC, de Jong PE, Kallenberg CGW. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-trimoxazole Wegener Study Group. N Engl J Med. 1996;335:16-20.
29. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med. 1990;113:656-663.
30. Heeringa P, Brouwer E, Tervaert JWC, Weening JJ, Kallenberg CG. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int. 1998;53:253-263.
31. Brouwer E, Huitema MG, Klok PA, et al. Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model. J Exp Med. 1993;177:905-914.
32. Jenne DE, Fröhlich L, Hummel AM, Specks U. Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis. FEBS Lett. 1997;408:187-190.
33. Wilharm E, Parry MA, Friebel R, et al. Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma. J Biol Chem. 1999;274:27331-27337.
34. Mizuno T, Kannan Y, Tokunaga M, et al. Role of hypothermia induced by tumor necrosis factor on apoptosis and function of inflammatory neutrophils in mice. Am J Physiol Regul Integr Comp Physiol. 2000;278:R157-R165.
35. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 1998;8:363-372.
36. Trimarchi M, Gregorini G, Facchetti F, et al. Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. Medicine (Baltimore). 2001;80:391-404.
37. Daoud MS, Gibson LE, DeRemee RA, et al. Cutaneous Wegener's granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol. 1994;31:605-612.
38. Blank M, Tomer Y, Stein M, et al. Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration. Clin Exp Immunol. 1995;102:120-130.
39. Reumaux D, Vossebeld PJ, Roos D, Verhoeven AJ. Effect of tumor necrosis factor-induced integrin activation on Fcγ receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood. 1995;86:3189-3195.
40. Noronha IL, Krüger C, Andrassy K, Ritz E, Waldherr R. In situ production of TNF-α, IL-1β, and IL-2R in ANCA-positive glomerulonephritis. Kidney Int. 1993;43:682-692.
41. Kunkel SL, Chensue SW, Strieter RM, Lynch JP, Remick DG. Cellular and molecular aspects of granulomatous inflammation. Am J Respir Cell Mol Biol. 1989;1:439-447.
42. Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest. 1992;90:693-698.
43. Abraham E, Carmody A, Shenkar R, Arcaroli J. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2000;279:L1137-L1145.
44. Tomosugi NI, Cashman SJ, Hay H, et al. Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1. J Immunol. 1989;142:3083-3090.
45. Heeringa P, Brower E, Kick PA, et al. Autoantibodies to myeloperoxidase aggravate mild immune mediated glomerular injury in the rat. Am J Pathol. 1996;149:1695-1706.
46. Foucher P, Heeringa P, Petersen AH, et al. Antimyeloperoxidase-associated lung disease-an experimental model. Am J Respir Crit Care Med. 1999;160:987-994.
47. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955-963.
48. Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med. 1998;244:209-216.
49. Schönermarck U, Lamprecht P, Csernok E, Gross WL. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology. 2001;40:178-184.
50. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001;44:1149-1154.
51. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology. 2002;41:1303-1307.
52. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488-498.
53. Elliott JD, Lockwood CM, Hale G, Waldmann H. Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases. Autoimmunity. 1998;28:163-171.
54. Gaskin G, Pusey CD. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher. 2001;5:176-181.
55. Matic G, Michelsen A, Hofmann D, et al. Three cases of c-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment. Ther Apher. 2001;5:68-72.
56. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001;44:2836-2840.